Hepatic Encephalopathy

Clinical Challenges and Opportunities

Edited by
January 2023
160 pages
  • ISBN978-3-0365-6338-1 (Hardback)
  • ISBN978-3-0365-6339-8 (PDF)

This book is a reprint of the Special Issue Hepatic Encephalopathy: Clinical Challenges and Opportunities that was published in

Medicine & Pharmacology
Public Health & Healthcare

Hepatic encephalopathy (HE) is a complex neurological syndrome, characteristic of patients with liver disease, that causes a wide and complex spectrum of nonspecific neurological and psychiatric manifestations, ranging from a subclinical entity such as minimal or covert hepatic encephalopathy to a deep form in which a complete alteration of consciousness can be observed: overt hepatic encephalopathy. Both minimal and overt hepatic encephalopathy have a high impact on patients, caregivers, and national health services, driving substantial consumption of economic resources. In this Special Issue, we discussed the current state-of-the-art research, address ongoing knowledge gaps, and ongoing controversies related to the pathogenesis, diagnosis, and therapeutic management of hepatic encephalopathy.

  • Hardback
© 2022 by the authors; CC BY-NC-ND license
hyperammonemia; liver; mitochondria; ketogenesis; gluconeogenesis; brain energy crisis; cirrhosis; liver disease; epidemiology; hepatic encephalopathy; transjugular portosystemic intrahepatic shunt; liver cirrhosis; minimal hepatic encephalopathy; nerve conduction; thermal sensitivity; autonomic testing; n/a; cirrhosis; bile acids; antibiotic resistance; enema; capsules; hospitalizations; cognitive function; liver failure; encephalopathy; delirium; coma; cirrhosis; porto-sinusoidal vascular liver disease; idiopathic non-cirrhotic portal hypertension; portal vein thrombosis; hepatic encephalopathy; porto-systemic shunt; cirrhosis; sarcopenia; myosteatosis; hepatic encephalopathy; hepatic encephalopathy; protein caloric-malnutrition; sarcopenia; dietary intervention; cirrhosis; mortality; minimal hepatic encephalopathy; cirrhosis; quality of life; sleep disorders; therapy; non-absorbable disaccharides; rifaximin